- Findings from the RELIEF study in France showed for the first time, in the largest retrospective analysis of its kind of nearly 75,000 people living with diabetes, use of the FreeStyle Libre system ...

- The FreeStyle Libre 3 system automatically delivers real-time, up-to-the-minute glucose readings, unsurpassed 14-day accuracy[1] and optional glucose alarms directly to smartphones[2] for people ...

- U.S. Centers for Medicare & Medicaid Services (CMS) reimbursement expands access of the FreeStyle Libre 2 system to Medicare patients[1] to better manage their diabetes - The FreeStyle Libre 2 ...

The new Flash Glucose Monitoring System enables patients to wear the sensor for up to 14 days compared with the existing FreeStyle Libre System that was approved for 10-day wear. Abbott announced that ...

Abbott Laboratories ABT presented late-breaking clinical data that demonstrate the FreeStyle Libre 3 system is the most accurate 14-day continuous glucose monitor. The results were presented at the ...

Abbott Laboratories ABT recently announced that its FreeStyle Libre 3 sensor integrated with the mylife Loop solution — building a smart, automated process to deliver insulin based on real-time ...

The FDA has approved the FreeStyle® Libre 2 integrated continuous glucose monitoring system (Abbott) for adults and children ≥4 years of age with diabetes. The Food and Drug Administration (FDA) has ...

A new study published in US Endocrinology found Abbott’s continuous glucose monitoring system, the FreeStyle Libre, demonstrated significant cost savings for diabetic care compared to traditional ...

"The best healthcare solution is the one that helps the most people, which is why we designed our FreeStyle Libre portfolio with access and affordability in mind from the very beginning," said ...

Abbott announced new late-breaking data demonstrating use of its FreeStyle Libre system, the world's leading sensor-based glucose monitoring technology, is associated with significant reduction in ...

ABBOTT PARK, Ill., Sept. 28, 2020 /PRNewswire/ -- Abbott (NYSE: ABT), the worldwide leader in continuous glucose monitoring (CGM) technology, 8 announced today it has secured CE Mark (Conformité ...